Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Eye disorders – page 24

  • 373 clinical trials
  • 123 recruiting
  • 138 conditions
  • 27 countries

Conditions in this area

138 conditions with trials, the busiest first

Conjunctivitis allergic34Sjogren's syndrome31Endocrine ophthalmopathy26Neovascular age-related macular degeneration23Giant cell arteritis18Seasonal allergy17Uveal melanoma17Dry age-related macular degeneration16Rhinitis allergic16Diabetic retinal oedema13Dry eye12Age-related macular degeneration11Retinitis pigmentosa11Asthma10Graves' disease10Myopia10Glaucoma8Open angle glaucoma8Uveitis8Immunoglobulin G4 related disease7Behcet's syndrome6Cataract6Mite allergy6Neuromyelitis optica spectrum disorder6+114

Clinical trials in Eye disorders

373 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

373 clinical trials

Optic glioma

Not recruiting

Study on the Safety and Effectiveness of Nerve Growth Factor CHF6467 for Children and Young Adults with Optic Pathway Glioma

Investigational
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Nerve growth factor, recombinant (R100E)
  • Sponsor:Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Exudative retinopathy

Not recruiting

Study on Bevacizumab Injections for Patients with Coats' Disease

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Bevacizumab
  • Sponsor:Fondation A De Rothschild

Cataract

Not recruiting

Comparison of preservative-free versus preserved dexamethasone and diclofenac eye drops in patients after cataract surgery

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:65+ years
  • Substances:Dexamethasone
  • Sponsor:UZ Leuven

Retinal vein occlusion

Not recruiting

Study on the Effect of Aflibercept Injections in Patients with Central Retinal Vein Occlusion (CRVO) and Spontaneous Retinal Arterial Pulsations (SRAPs)

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Fondation A De Rothschild

Neovascular age-related macular degeneration

Not recruiting

Study on Faricimab and Aflibercept for Patients with Neovascular Age-Related Macular Degeneration Receiving Frequent Aflibercept Treatment

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Medical University Of Graz

Retinitis pigmentosa+1

Not recruiting

Study of AAVB-081 and Prednisolone for Patients with Usher Syndrome Type 1B Retinitis Pigmentosa

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Prednisolone
  • Sponsor:Aavantgarde Bio S.r.l.

Giant cell arteritis

Not recruiting

Study on Tocilizumab and Steroids for Patients with Giant Cell Arteritis and Cerebrovascular Involvement

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Tocilizumab
  • Sponsor:Assistance Publique Hopitaux De Paris

Wolfram syndrome

Not recruiting

Study on the Effects of Sodium Valproate for Hearing Preservation in Patients with Wolfram Syndrome

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Sodium Valproate
  • Sponsor:Centre D'Etude Des Cellules Souches

Open angle glaucoma+1

Not recruiting

Study Comparing Bimatoprost Eye Drops with Lumigan for Patients with Chronic Open-Angle Glaucoma or Ocular Hypertension

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bimatoprost
  • Sponsor:Genetic S.p.A.

Conjunctivitis allergic+1

Not recruiting

Study on Mannan-Conjugated Birch Pollen Allergoids for Adolescents and Adults with Birch Pollen-Induced Allergic Rhinitis or Rhinoconjunctivitis

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Betula Pendula Pollen Allergoid, Mannan-Conjugated, Polymerised
  • Sponsor:CCDRD Cooperative Clinical Drug Research and Development AG

Neovascular age-related macular degeneration

Not recruiting

Study on the Effects of RGX-314 Gene Therapy Compared to Aflibercept and Ranibizumab for Patients with Neovascular Age-Related Macular Degeneration

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Sjogren's syndrome

Not recruiting

Study on Hydroxychloroquine, Leflunomide, and Mycophenolate Mofetil for Patients with Primary Sjogren's Syndrome

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Leflunomide
  • Sponsor:Assistance Publique Hopitaux De Paris

Substances studied in this area

The therapies tested most often in Eye disorders trials.

Aflibercept27 clinical trialsSodium Chloride16 clinical trialsPrednisone14 clinical trialsRanibizumab14 clinical trialsDexamethasone11 clinical trialsDexamethasone Phosphate10 clinical trialsFluorescein Sodium10 clinical trialsPrednisolone10 clinical trialsNivolumab8 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.